Navigation Links
Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections

AUSTIN, Texas, July 27 /PRNewswire/ -- Patton Medical Devices, manufacturer of the i-port(R) and a leader of injection port therapy, announced today that they have entered into a partnership agreement with Unomedical, a leading manufacturer of single use medical devices used in the treatment of diabetes.


The two companies are working together to design and develop the i-port Advance(TM), the first subcutaneous injection port for people taking multiple daily injections to include a disposable inserter, that will assist patients with the application process and eliminate the need for manual insertion. The i-port Advance(TM), similar in design to the i-port(R), will also provide improved features which may help to reduce insertion pain and enhance the user experience.

"We are excited about working with a global, industry leading company such as Unomedical which, like us, believes in the injection port therapy market opportunity. With the i-port Advance(TM), users will experience an application feature similar to the inserter technology used to apply most insulin pump infusion sets. Based on feedback received from people living with diabetes, diabetes educators, physicians and hospital nurses, we believe the i-port Advance(TM) may help alleviate the potential for error from an improper manual insertion while providing the key benefit of having a simple way to deliver injections without the need to puncture the skin for each dose of medication." John Burns, President, Patton Medical Devices

As part of the agreement, Patton Medical Devices has exclusive rights to market and distribute the i-port Advance(TM) both in the United States and international markets while Unomedical has exclusive manufacturing rights.

"With the i-port Advance(TM) we can offer more people with diabetes access to a user-friendly and safe device designed for safe delivery of insulin. The dedication of Patton Medical Devices towards promoting injection port therapy combined with our expertise in designing and manufacturing high quality insulin delivery devices is a perfect match for bringing this new and innovative product to the market." John M Lindskog, Vice President & General Manager, Unomedical Infusion Devices

Device demonstrations of the i-port Advance(TM) will be unveiled at the annual American Association of Diabetes Educators Conference in Atlanta, Georgia August 4-8, 2009. Both companies are working together to have the i-port Advance(TM) commercially available in the United States and other select countries by April 2010.

About Patton Medical Devices

Headquartered in Austin, Texas, Patton Medical Devices is the manufacturer of the i-port(R) Injection Port. For people taking injections who want to minimize the intrusion of injections on daily life, the i-port(R) is the only product of its kind conceived by a person with diabetes that offers a simple, convenient way to eliminate the need to puncture the skin with each dose of medication. The i-port(R) lets patients focus on living their lives instead of the challenges associated with the next shot. i-port(R) is a registered trademark and i-port Advance(TM) is a trademark of Patton Medical Devices. For more information about Patton Medical Devices, its products and services, visit or

About Unomedical

Unomedical a/s, located in Denmark, specializes in the development and manufacturing of single use devices used in the treatment of diabetes. It has been a leading provider of infusion sets for insulin pump therapy worldwide since the mid 1980's, and currently manufactures the infusion sets Quick-set(R), inset(R) and inset(R) 30 among others. Unomedical a/s is a business unit of ConvaTec. inset(R) is a registered trademark of Unomedical a/s and the Quick-set(R) is a registered trademark of and exclusively distributed by Medtronic Minimed. For more information about Unomedical, its products and services, visit or

About the i-port(R) Injection Port

The i-port(R) Injection Port is a prescription only device for use by people requiring multiple daily, subcutaneous injections of physician-prescribed medications, including insulin. The i-port(R) may be a helpful treatment delivery tool for anyone who wants to minimize the intrusion of daily injections.

The i-port(R) should not be worn for longer than 72 hours. The most serious risks when using the i-port(R) include infection and the potential for poor medication delivery if not properly applied. For people with diabetes, the poor medication delivery may result in abnormally high or low blood sugar levels. If you experience these or any other problems when using the i-port(R), tell your doctor.

SOURCE Patton Medical Devices
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
2. Varian Medical Systems to Showcase a Wide Spectrum of New and Updated Products That Improve Radiotherapy Treatment Processes at 2009 AAPM Meeting
3. Symphony Medical Changes Name to CardioPolymers, Inc.
4. Environmental Tectonics Corporation Announces Promotion of Don R. Webber to VP of Sales for their BioMedical Division
5. Regado Biosciences Expands Medical Advisory Board
6. BioMS Medical announces second quarter 2009 results
7. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
8. American Medical Informatics Association (AMIA) Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certification
9. Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test
10. Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries
11. IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors
Post Your Comments:
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):